Sanofi

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Yahoo Finance · 31/07/2026 · lire l'article ↗

Sanofi SA (SNY) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance ...

Sanofi SA (SNY) reports double-digit Q2 growth and raises full-year outlook, while navigating R&D challenges and strategic alliance discussions.

Yahoo Finance · 30/07/2026 · lire l'article ↗

Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks

SNY beats on Q2 earnings and sales as Dupixent tops euro 5B in quarterly sales for the first time. The company also raises its 2026 outlook.

Yahoo Finance · 30/07/2026 · lire l'article ↗

Press Release: Sanofi’s half-year financial report for 2026

Sanofi’s half-year financial report for 2026 Paris, July 30, 2026. Sanofi announces that its half-year financial report for the period ending June 30, 2026, is now available online and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the US Securities and Exchange Commission (SEC) under form 6-K. This document may be found on www.sanofi.com and downloaded from the “Investors” page, under the heading “Financial Reports and Other Publications

Yahoo Finance · 30/07/2026 · lire l'article ↗

Sanofi Q2 Earnings Call Highlights

Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongo

Yahoo Finance · 30/07/2026 · lire l'article ↗

Sanofi (ENXTPA:SAN) Stops Amlitelimab In Eczema And Expands Aqemia AI Pact

Sanofi discontinued clinical development of amlitelimab in atopic dermatitis, citing efficacy and safety assessments. The company expanded its AI driven drug discovery collaboration with Aqemia to pursue new drug candidates. Both decisions affect Sanofi's dermatology pipeline and its approach to using generative AI in R&D. Sanofi (ENXTPA:SAN), trading at around €76.03, is adjusting its research focus as it pulls amlitelimab from atopic dermatitis trials and leans further into AI supported...

Yahoo Finance · 25/07/2026 · lire l'article ↗